lifestyle.small-bizsense.com

Author: LEADS BIOLABS CO. LTD

Leads Biolabs’ PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies

April 21, 2026
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results

April 9, 2026
Leads Biolabs’ Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China’s High-Incidence Cancer

March 9, 2026
Median PFS Trending Beyond One Year: Leads Biolabs’ LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting

December 7, 2025